How does survodutide work?

Survodutide is an experimental once-a-week drug that switches on two receptors, GLP-1 and glucagon. The GLP-1 side is the appetite and blood sugar route known from semaglutide. The glucagon side is studied for burning more energy and for effects on the liver. This site's profile says its half-life is about 6 days. Its molecular weight is about 4,900 daltons. A 46-week obesity study in 387 adults without diabetes found an average weight change of down 14.9% at 4.8 milligrams a week, versus down 2.8% on a dummy shot. A 48-week study in 293 adults with MASH (a fatty liver disease with liver damage) found the liver improved under the microscope, without more scarring, in 47 to 62% on survodutide versus 14% on a dummy shot. A large final-stage study, SYNCHRONIZE-MASLD, in 216 adults, found 84% versus 24% cut their liver fat by at least 30%, with body weight down 12.2% versus down 1.0% at 48 weeks. It is not FDA approved. This FAQ does not invent a dose. Full record at /compounds/survodutide.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.